Introduction
============

Non-alcoholic fatty liver disease (NAFLD) is diagnosed increasingly worldwide and is considered to be the most common liver disorder in the West ([@B51]). NAFLD refers to a spectrum of hepatic disorders, ranging from simple hepatic steatosis with no apparent specific symptoms to hepatocellular carcinoma ([@B28]). Hepatic steatosis is caused by abnormal accumulation of triglycerides (TG) in the liver due to chemical exposures other than excessive alcohol consumption. This accumulation of TG in vesicles impairs hepatic function and makes the liver highly susceptible to other injuries related to metabolic syndrome and systemic energy metabolism ([@B43]). Simultaneously, it affects the local immune system and that may lead to more severe autoimmune diseases ([@B3]). From a metabolic point of view, steatosis occurs when the fatty acids (FAs) influx or synthesis in the liver exceeds the capacity to clear them. The metabolic pathways leading to the development of hepatic steatosis are multiple, including enhanced non-esterified FA release from adipose tissue (lipolysis), increased *de novo* FAs (lipogenesis) and decreased β-oxidation ([@B20]).

Some toxicogenomics studies have been reported on drug-induced steatosis (DIS) or steatohepatitis (DISH) ([@B34]; [@B61]; [@B23]; [@B50]), however, the mechanisms of action leading to steatosis are not fully understood. To support toxicity evidence with mechanistic pathways and mode of action for drug safety and risk assessment, the OECD has recently developed the adverse outcome pathway (AOP) concept. The AOP concept involves all the essential steps that take place in the toxicity pathways, from the molecular initiating event (MIE) at the protein or gene level, passing through organelle effect, cellular, tissue, organ and finally population effect. One key principle is that AOPs are chemical agnostic pathways ([@B65]). Steatosis is one of the AOPs highly investigated and although AOPs are chemical agnostic pathways, the activation of some specific molecules, which lead to the over or under regulation of key events (KEs) with steatosis as a final outcome has been reported on the OECD AOP website^[1](#fn01){ref-type="fn"}^.

In this study, we decided to analyze transcriptomic data on a set of 28 drugs tested in primary human hepatocytes and suspected to cause steatosis. In order to obtain an overall understanding of the disease, steatosis-producing chemicals were compiled and analyzed together. An interesting feature is that compounds have been studied at different times and doses, so we were able to perform a time-series analysis at the gene level but also at the pathway level. The distinction between time points and concentrations can explain how the different KEs affect one another, which will help in explaining complex hepatotoxicity. The results of our analysis support previously reported finding and provide new hypotheses that could be investigated further.

Materials and Methods {#s1}
=====================

Chemicals
---------

For the current analysis, 28 compounds were selected according to their ability to induce steatosis in primary human hepatocytes (PHH) and the availability of gene expression data in the TG-GATEs (Toxicogenomics Project--Genomics-Assisted Toxicity Evaluation System) database ([@B25]). Furthermore, seven non-steatotic compounds available in TG-GATEs were also included according to the study carried out by [@B54] and [@B55] as negative controls. The negative controls have been associated with other histopathological observations in rat *in vivo* such as necrosis, cellular infiltration, fibrosis and granuloma (**Supplementary Table [S1](#SM2){ref-type="supplementary-material"}**). The TG-GATEs database contains data from PHH exposed to those compounds and collected using Affymetrix HG U133 Plus 2.0 gene expression microarrays. Two replicates were tested at three dose levels (low, medium, and high) and at three time points (2, 8, and 24 h after initial dosing). For each experiment, corresponding untreated controls are also tested. The 35 chemicals used in the study are summarized in **Table [1](#T1){ref-type="table"}**. The specific dose and times can be found in **Supplementary Table [S2](#SM3){ref-type="supplementary-material"}**.

###### 

Compounds used in the analysis.

  Compound name        Abbreviation   Cas No.      Sample             Reference
  -------------------- -------------- ------------ ------------------ -----------
  Allyl Alcohol        AA             107-18-6     Steatosis          ([@B68])
  Amiodarone           AM             1951-25-3    Steatosis          ([@B3])
  Acetaminophen        APAP           103-90-2     Steatosis          ([@B19])
  Acetamide            AAA            60-35-5      Steatosis          ([@B71])
  Amitriptyline        AMT            50-48-6      Steatosis          ([@B69])
  Aspirin              ASA            50-78-2      Steatosis          ([@B59])
  Coumarin             CMA            91-64-5      Steatosis          ([@B55])
  Colchicine           COL            64-86-8      Steatosis          ([@B58])
  Clomipramine         CPM            303-49-1     Steatosis          ([@B69])
  Cyclosporin A        CSA            59865-13-3   Steatosis          ([@B40])
  Clozapine            CZP            5786-21-0    Steatosis          ([@B72])
  Diltiazem            DIL            42399-41-7   Steatosis          ([@B16])
  Disulfiram           DSF            97-77-8      Steatosis          ([@B5])
  Ethanol              ETN            64-17-5      Steatosis          ([@B15])
  Ethinylestradiol     EE             57-63-6      Steatosis          ([@B45])
  Ethionamide          ETH            536-33-4     Steatosis          ([@B71])
  Hydroxyzine          HYZ            68-88-2      Steatosis          ([@B55])
  Imipramine           IMI            50-49-7      Steatosis          ([@B69])
  Lomustine            LS             13010-47-4   Steatosis          ([@B32])
  Methapyrilene        MP             91-80-5      Steatosis          ([@B13])
  Methyltestosterone   MTS            58-18-4      Steatosis          ([@B56])
  Phenylbutazone       PhB            50-33-9      Steatosis          ([@B9])
  Rifampicin           RIF            13292-46-1   Steatosis          ([@B64])
  Terbinafine          TBF            91161-71-6   Steatosis          ([@B12])
  Tetracycline         TC             60-54-8      Steatosis          ([@B3])
  Vitamin A            VA             68-26-8      Steatosis          ([@B39])
  Valproic acid        VPA            99-66-1      Steatosis          ([@B66])
  Pirinixic acid       WY             50892-23-4   Steatosis          ([@B11])
  Carbamazepine        CBZ            298-46-4     Negative Control   ([@B9])
  Diclofenac           DFNa           15307-86-5   Negative Control   ([@B9])
  Indomethacin         IM             53-86-1      Negative Control   ([@B14])
  Naproxen             NP             22204-53-1   Negative Control   ([@B9])
  Nifedipine           NIF            21829-25-4   Negative Control   ([@B7])
  Nimesulide           NIM            51803-78-2   Negative Control   ([@B9])
  Sulindac             SUL            103-90-2     Negative Control   ([@B9])

The reference corresponds to the publication in which drug-induced hepatic steatosis or negative control has been reported.

Microarray Data Analysis
------------------------

All data were analyzed using the robust multi-array average (RMA) methodology in the Bioconductor R package for background-adjusted, normalized, and log-transformed perfect matched values of individual probes from the Affymetrix Human Genome U133 Plus 2.0 array ([@B27]). 54,675 probes corresponding to 19,945 uniquely annotated Gene Symbol IDs define each microarray. There is a total of 225 experiments according to concentration, time of exposure and compound used for the treatment. These experiments where analyzed in four steps: (1) all the experiments have been normalized concertedly. Such global normalization highlights the most important genes, which are those affected by the toxicity of more than one compound, and most likely in more than one time point and/or concentration ([@B33]). When dealing with gene expression microarray data, results can be affected by small differences in any number of non-biological variables, i.e., reagents or different technicians. (2) The two replicates per compound and condition were averaged. (3) Batch effect was accounted in the design matrix, reducing the bias effect on further steps of the analysis similarly to what has been performed by [@B21]. Concretely, for each gene a linear model following Eq. 1 (corresponding to a *t*-test comparison between two groups) was performed ([@B52]). (4) Subsequently, differentially expressed genes (DEGs) were calculated by dividing the average signal obtained from the chemical exposed group by the average signal from control receiving the vehicle only. The Student *t*-test was used to calculate the *p* value which was corrected by Bonferroni multiple testing. Finally, DEGs were selected by considering the *p* values less than 0.05 and fold-changes higher than 1.5. Genes that met these criteria also in the negative control set were removed from the deregulated gene's list for steatosis, assuming that these genes were not related to steatosis.
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Time-Series Analysis
--------------------

To characterize the deregulation of genes related to steatosis over time, after drug administration, a time-series analysis was performed on the 28 compounds using the package MasigPro in R ([@B47]). This analysis was performed for each compound individually. With MasigPro, genes with significant temporal expression changes were selected and their variance at the different concentration (low, medium, and high) were analyzed. As a first step, a regression on time for each gene taking all the variables present in the model, hence using all the genes, was performed. A false discovery rate (FDR) method was used to select genes with a value less than 0.05. Moreover, for each gene the best regression model was selected using stepwise regression. A backward method was used; therefore all genes were used as variables to initialize the modeling (*p*-value \<0.05 were considered). In a final step, the R-squared of the regression model was used as cut-off value in order to reduce the amount of false positive findings (genes). R-squared was set to 0.6 to allow flexibility to the regression model, since we are working with all the compounds associated with steatosis, as suggested by MasigPro. Overall, MasigPro provides information on genes that change over time and in respect to the control. Such analysis can be visualized, plotting DEG of every single gene for each compound studied according to time and dose.

Gene Set and Pathway Analysis
-----------------------------

In addition to the DEG and the time-series analysis, a pathway analysis was performed based on our gene expression analysis for the 28 compounds. Compared with the individual gene/molecule-based approach, pathway analysis is more sensitive, consistent and informative on the outcomes studied ([@B42]). In our study, the parametric statistical analysis model (PAGE) was used ([@B31]). The method is based on a modified Gene Set Enrichment Analysis (GSEA). A gene randomization test was applied to the gene expression data, in which the significance of gene sets is identified for pathways (computing permutations of gene labels or a parametric distribution over genes). The database used for the study of the pathways was KEGG, which is a database resource that integrates genomic, chemical and systemic functional information for a large set of pathways ([@B29]). In order to obtain a quantitative result of the compound's effect over the pathways, a Gene Fold Enrichment (GFE) score was calculated. This score divided the number of genes deregulated by the total number of genes of the pathway being analyzed and then multiply by the statistical mean for the same pathway. Pathview, a tool set for pathway-based data integration and visualization, was used within the GAGE package in R for visualization of the genes deregulated in the KEGG pathway ([@B41]). In our context, no specific pathway has been developed for steatosis in KEGG or other pathway databases. So, we have considered the NAFLD pathway, which is the closest pathway to steatosis for the visualization.

Clustering
----------

Previous studies have shown that the use of gene expression clustering can group samples in clusters that may lead to a good prediction of the gene-outcome relationship ([@B1]; [@B22]). Therefore, a pathway analysis was also performed on the set of compounds after clustering. Clustering was based on the logarithm base 2 of the fold change of the gene expression at the different conditions. The Euclidian distance implemented in Ward.D2 in R method was used. The clustering method was performed in all compounds containing information for at least 2 timepoints, hence excluding clozapine (CZP) from the analysis, which has been studied only for 1 timepoint. The clustering has been performed separately for the different time points. The clustering shown in **Figure [5](#F5){ref-type="fig"}** was performed on the compounds at 24 h. The determination of the number of clusters was done by the *elbow method*. A range of *k* values from 1 to 10, *k* value being the number of chemical belonging to a cluster, were considered in our analysis. For each *k* value the sum of squared errors (SERs) was calculated and the selection of the number of cluster was based on a compromise between the number of clusters and low SER. *K* = 4 was selected as it showed a close to maximum separation of the samples and low SER.

Results
=======

DEG Analysis
------------

Firstly, we analyzed DEGs under all different conditions versus control for the 28 compounds with a global normalization of the 255 experiments (all together analysis). 742 genes are highly deregulated in at least one condition, i.e., one compound at a specific time and concentration (logFC ≥ 1.5 and with a FDR Bonferroni-corrected value ≤0.05).

For the pathway analysis, we looked specifically at the NAFLD pathway, a general pathway related to fatty liver, and for which steatosis might be related for some genes. Through the pathway enrichment analysis, many genes involved in the NAFLD are deregulated (**Figure [1](#F1){ref-type="fig"}**). Mapping the genes deregulated by the set of 28 compounds on the NAFLD pathway led to the observation that some genes are up regulated, in red (INSR, adipR, or PPARα), by a large set of compounds (AAA, PhB, CPM, and HYZ), whereas another set of genes is more often down regulated, in green (LXR, PI3K, FAS, CASP8, IKKB, and BAX) by others compounds (VA, ASA, and APAP). There are several compounds that show opposite effects by up/down-regulating the same genes. This is the case of CYP2E, AMPK and other mitochondrial genes. This supposes that there are different mechanisms of action that can trigger steatosis.

![Non-alcoholic fatty liver disease (NAFLD) pathway view. After a GAGE analysis of the gene expression data amongst the highest scored pathways (*p* \< 0.05). All the compounds suspected to produce steatosis at middle concentration and time 8 h are plotted. All the gene expressions have been normalized from --1 to 1, centered at 0. Green boxes correspond to a down regulation of the genes by a chemical and red box an up-regulation of the genes.](fgene-09-00396-g001){#F1}

Gene Ontology pathway enrichment was also performed with the 742 genes in order to get an impression of the biological processes that were affected (**Figure [2](#F2){ref-type="fig"}**). The enrichment in terms of pathways based on GO terms was used in this study. At the first level of the pathway hierarchy, the deregulated genes are related to several pathways, including cellular process, metabolic process, localization, developmental process and immune system process. The two most significant are the cellular processes and metabolic processes. Within metabolic processes, primary metabolic processes are the most significant pathways targeted by the deregulated genes. In primary metabolic processes, the two most targeted pathways are nucleobase-containing compound metabolic processes and lipid metabolic processes. The latest contains steroid metabolic process, phospholipids metabolic process and FA metabolic process. Looking into the specific pathways, the most represented in the GO analysis are FA β-oxidation and acetyl-CoA metabolic process. So, we can note that many genes deregulated by the set of compounds affect lipids and FAs and play a role in steatosis.

![Gene Ontology pathway enrichment for *in vitro* human hepatocytes. **(A)** The two main blocks of pathways that are deregulated according to the genes that have a log2FC above absolute value 1.5 and a *q*-value ≤0.05, are affecting the metabolic pathways as well as the cellular processes in general. **(B)** The pathways affected within the metabolic pathways are shown here, and they affect mainly the primary metabolic process. **(C)** Pathways represented within primary metabolic process.](fgene-09-00396-g002){#F2}

Time-Series Analysis
--------------------

In the previous analysis, the outcomes were analyzed independently of time and dose. To investigate the evolution of the expression over time, a time-series analysis was carried out using the R package MasigPro. After removing the genes involved in cell cycle according to GO biological processes (see **Supplementary Table [S3](#SM4){ref-type="supplementary-material"}**) ([@B6]), MasigPro detected 48 genes with significant temporal expression changes (**Table [2](#T2){ref-type="table"}**). These genes are mainly involved in metabolic and immune system pathways. Among them, some genes have previously been reported to play a hepatotoxic role such as MYADM ([@B44]), SLC51B ([@B4]), PRDX6 (([@B46]; [@B48]), OSBPL9 ([@B24]), GPAT3 ([@B30]), TMEM135 ([@B17]), DLGDA5 ([@B38]), BCO2 ([@B26]), IDH3G ([@B49]), NEURL1B ([@B36]), and TSPAN6 ([@B67]). An extensive work done in rodents related to steatosis adverse outcome described how OSBPL proteins promote the development of NAFLD in mice ([@B62]). Finally, the role of GPTA proteins has been reported to play a role in the development of hepatic steatosis ([@B70]).

###### 

Deregulated genes over time and dose.

  Entrez-ID   Gene symbol   Gene full name
  ----------- ------------- -------------------------------------------------------------------------
  91663       MYADM         Myeloid associated differentiation marker
  27286       SRPX2         Sushi repeat containing protein, X-linked 2
  10491       CRTAP         Cartilage associated protein
  84803       GPAT3         Glycerol-3-phosphate acyltransferase 3
  9787        DLGAP5        DLG associated protein 5
  83875       BCO2          Beta-carotene oxygenase 2
  3161        HMMR          Hyaluronan mediated motility receptor
  3421        IDH3G         Isocitrate dehydrogenase 3 (NAD(+)) gamma
  6790        AURKA         Aurora kinase A
  28998       MRPL13        Mitochondrial ribosomal protein L13
  54492       NEURL1B       Neuralized E3 Ubiquitin Protein Ligase 1B
  2633        GBP1          Guanylate binding protein 1
  10112       KIF20A        Kinesin family member 20A
  80114       BICC1         BicC family RNA binding protein 1
  65084       TMEM135       Transmembrane protein 135
  7105        TSPAN6        Tetraspanin 6
  9615        GDA           Guanine deaminase
  9488        PIGB          Phosphatidylinositol glycan anchor biosynthesis class B
  55771       PRR11         Proline rich 11
  11167       FSTL1         Follistatin like 1
  2519        FUCA2         Fucosidase, alpha-[L]{.smallcaps}-2, plasma
  9588        PRDX6         Peroxiredoxin 6
  79594       MUL1          Mitochondrial E3 ubiquitin protein ligase 1
  51292       GMPR2         Guanosine monophosphate reductase 2
  81610       FAM83D        Family with sequence similarity 83 member D
  55872       PBK           PDZ binding kinase
  59          ACTA2         Actin, alpha 2, smooth muscle, aorta
  7802        DNALI1        Dynein axonemal light intermediate chain 1
  5445        PON2          Paraoxonase 2
  3242        HPD           4-hydroxyphenylpyruvate dioxygenase
  28998       MRPL13        Mitochondrial ribosomal protein L13
  11004       KIF2C         Kinesin family member 2C
  1606        DGKA          Diacylglycerol kinase alpha
  10158       PDZK1IP1      PDZK1 interacting protein 1
  9122        SLC16A4       Solute carrier family 16 member 4
  23082       PPRC1         Peroxisome proliferator-activated receptor gamma, coactivator-related 1
  123264      SLC51B        Solute carrier family 51 beta subunit
  6372        CXCL6         C-X-C motif chemokine ligand 6
  79053       ALG8          ALG8, alpha-1,3-glucosyltransferase
  9928        KIF14         Kinesin family member 14
  788         SLC25A20      Solute carrier family 25 member 20
  114883      OSBPL9        Oxysterol binding protein like 9
  55526       DHTKD1        Dehydrogenase E1 and transketolase domain containing 1
  56922       MCCC1         Methylcrotonyl-CoA carboxylase 1
  10351       ABCA8         ATP binding cassette subfamily A member 8
  501         ALDH7A1       Aldehyde dehydrogenase 7 family member A1
  516         ATP5G         ATP Synthase Membrane Subunit C Locus 1
  9488        PIGB          Phosphatidylinositol glycan anchor biosynthesis class B

Our results confirm previous transcriptomics analysis in rodents with deregulation of genes such as GPAT, KIF, CXCL, and SLC family genes ([@B55]) and OSBP family that alters the lipid metabolism in mice ([@B8]).

An example of the visualization of the time-series analysis is shown in **Figure [3](#F3){ref-type="fig"}** for neutralized E3 ubiquitin protein ligase 1B (NEURL1B) after exposure to the 28 compounds. We can observe that NEURL1B is regulated in positive direction over time for many compounds. Other examples are presented in supplementary information (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**).

![De-regulation over time of the 28 steatotic chemicals for the selected protein, NEURL1B, from the time-series analysis. The *y*-axis indicates the normalized expression value of the gene at every time-point, 2, 8 and 24 h (*x*-axis), where the different colors indicate the dosages (red indicates control, blue low dose, purple middle dose, and green high dose). It shows a time dependency of the protein expression and compound specific dose effect. However, it does not show a systematic change on the gene expression due to dose. For some compounds only two time-point samples were taken.](fgene-09-00396-g003){#F3}

From the gene list, other genes might play a role in steatosis and could be investigated further. For example, ALDH7A1 is highly deregulated in a time/dose-dependent manner. This gene is involved in oxidoreductase mechanisms and in protection of cell against oxidative stress by metabolizing a number of lipid peroxidation-derived aldehydes and could lead to steatosis. For some compounds, i.e., AM, APAP, LS, and MP, the de-regulation of ALDH7A1 is also dependent on the treatment concentration. The deregulation of these proteins will lead to a higher production of lipids, which together with a reduction of beta-oxidation of lipids could promote their accumulation in cells. Finally, a set of compounds deregulated some genes differently, suggesting that they trigger steatosis through another mechanism. This is the case for example for DSF and EE, which showed a weak deregulation of OSBL9 and a higher deregulation of the ALDH7A1.

Some genes known to be commonly associated to steatosis in human are not in this top list. This is the case for example of PNPLA3, which does not appear as one of the highest deregulated genes in our study. The genetic variation in PNPLA3 has been previously shown to play a role in the increase of FA accumulation in liver leading to steatosis ([@B53]). So, the lack of the specific polymorphism related to susceptibility to steatosis in the cells used could explain the non-deregulation of this gene in our study.

Overall, this list of genes provides an insight into the mechanistic pathways already related to steatosis, as well as new hypotheses that can be analyzed further. Interestingly, the expression for many genes vary a little from control as a function of dose and the difference in the pattern of expression between control and treatment is relatively low. This confirmed a previous analysis showing that the doses differences between treatments in rat primary hepatocytes explain less than 0.1% of variation in all cases ([@B63]). One possible explanation is primary hepatocytes rapidly dedifferentiate ([@B35]) which could generate a gradual down regulation of hepatocyte function over time in culture.

Pathway Time-Series Analysis
----------------------------

Due to the broad pharmacological and physicochemical characteristics of the compounds used for this study, we developed a new type of time-series analysis at the pathway level. For this purpose, all the compounds were analyzed to obtain the most significantly deregulated pathways including their corresponding GFE score (**Figure [4](#F4){ref-type="fig"}**).

![Time-series pathway analysis based on GFE and depending on the concentration. The *y*-axis displays the overall Gene Fold Enrichment.](fgene-09-00396-g004){#F4}

At low concentration, pathways such as FA degradation and oxidative phosphorylation start to get down regulated. The deregulation of the oxidative phosphorylation is prominently affecting the mitochondria, therefore reducing the activity within this organelle, such as β-oxidation, which is the catabolic process through which FAs are broken down. The PIK3-Akt signaling pathway gets up regulated through the activation of the AMPK signaling pathway or downstream, Mtor signaling pathway, affecting the metabolism of the cell ([@B37]). At higher concentrations, other important pathways are affected. The steroid biosynthesis is up-regulate at middle and high dose. FA biosynthesis and FA elongation are also among the up regulated pathways. Hence more FAs and lipids are produced. In contrast, the protein processing in ER, known to be related to lipid homeostasis, is down regulated. Interestingly, several studies have previously shown the existence of comorbidities between liver diseases and cardiovascular (CDV) diseases ([@B2]). The deregulation of the renin-angiotensin system could explain part of the relation between steatosis and any possible CDV disease. Vitamin digestion and absorption is down regulated, which also points toward de-regulation in the FA β-oxidation. Also tyrosine metabolism, which is related to liver damage displays down-regulation. When the liver is damaged, phenylalanine cannot be converted to tyrosine. At this highest concentration, the adipocytokine signaling pathway and TNFα signaling pathway are deregulated, which indicates an activation of the cellular immune system. This immune system de-regulation may contribute the steatotic condition to move forward to other more severe drug-induced liver damages. Note that at high dose, cells often develop non-specific toxicity and the pathways altered may be not related solely to steatosis but also to other toxicity endpoints. The pathway analysis confirmed the little contribution of doses over time at the gene level observed previously, as the majority of the pathways deregulated in middle dose are also present in high dose.

Finally, to obtain a more characteristic view on the specific action points of the different compounds, we performed a similar analysis after clustering the compounds through the gene's signature similarity. Using the Euclidean distance based on the log2FC of the gene expression, all compounds were clustered in four sets (**Figure [5](#F5){ref-type="fig"}**).

![Clustering by Euclidean distance of the different compounds based on the logarithm in base 2 Fold Change of the gene expression for the different conditions. Each color represents a cluster. The *y*-axis is a measure of closeness of either cluster or individual data points.](fgene-09-00396-g005){#F5}

VPA was clustered separately. MP and AA formed a different cluster as well as APAP and COL. A final cluster contained the remaining compounds. This last cluster contains essentially drugs used to treat a variety of conditions, acting as immunosuppressant's, antineoplastic agents, antibiotics, biguanides and butylpyrazolidines.

After clustering, the pathway time-series analysis was performed on each of the four clusters (**Figure [6](#F6){ref-type="fig"}**). For the compounds of the larger cluster, cluster 1 (TBF, AMT, DIL, PhB, HYZ, CSA, WY, RIF, ASA, AM, AAA, EE, VA, TC, MTS, IMI, CPM, DSF, CMA, ETH, LS, ETN), at low concentrations of treatment metabolic pathways such as fat digestion and absorption, linoleic and linolenic acid metabolism, calcium signaling pathway and others are up regulated over time. Other pathways, such as FA metabolism, peroxisome, retinol metabolism, and some steroid metabolic pathways are down regulated. At higher concentrations from time 2 to 24 h, the FA metabolism, calcium signaling pathway and steroid hormone biosynthesis increase over time, showing a de-regulation of these pathways promoted by the treatment. The FA degradation pathway is down regulated. It means that the FAs inside the cell are increasing and there are no pathways to deplete them. The oxidative phosphorylation becomes down regulated over time. So, the oxidative conditions in the mitochondria are starting to be reduced at this concentration. Finally, at the highest concentration tested, many signaling pathways known to be steatosis-producing related are targeted. FoxO, MAPK, PPAR signaling pathways, are highly up regulated. Steroid hormone biosynthesis, FA biosynthesis, glycerophospholipid metabolism, glycosphyngolipid biosynthesis and other lipid metabolic pathways are also up regulated. Moreover, SNARE interactions in vesicular transport are also up regulated over time, which could indicate the internalization of the FAs into vesicles, and so accumulation inside the cells. In contrast, pathways, such as oxidative phosphorylation, vitamin digestions and absorption and FA degradation are down regulated over time.

![Time-series pathway analysis based on GFE and depending on the concentration for the four clustered of compounds. The *y*-axis displays the overall Gene Fold Enrichment.](fgene-09-00396-g006){#F6}

For cluster 2 (AA, MP) (**Figure [6](#F6){ref-type="fig"}**) at low concentrations the most highly up regulated pathways are the PI3K-Akt signaling pathway, the Mtor signaling pathway and the adipocytokine signaling pathway. Some metabolic pathways like FA degradation, peroxisome and retinol metabolism are down regulated. With the increasing concentration, steroid biosynthesis starts to be up regulated. At the highest concentration, glycolysis/gluconeogenesis, FA degradation, TNFα signaling pathway, tyrosine metabolism, peroxisome, PPAR signaling pathway and retinol metabolism become down-regulated over the time and FA metabolism, adipocytokine signaling pathway, MAPK signaling pathway, among others, become up-regulated. This could be explained by a lesser effect of these compounds. Therefore higher concentrations are needed in order to deregulate the cell to a steatotic pattern.

In the case of cluster 3 (APAP, COL) (**Figure [6](#F6){ref-type="fig"}**), at low concentrations, oxidative phosphorylation is highly down regulated, together with retinol metabolism and some lipid metabolism such as ether lipid metabolism and glycolysis/gluconeogenesis. On the other hand, FA elongation, TNFα signaling pathway, PI3K-Akt signaling pathway and sphingolipid signaling pathway and sphingolipid metabolism are highly up regulated. At higher concentrations, retinol metabolism continues to be down-regulated, glycolysis/gluconeogenesis, FA elongation are down-regulated and protein processing in the ER, steroid biosynthesis, SNARE interactions in vesicular transport among others are up regulated. These deregulations could affect the export of FAs to the exterior of the cell and their accumulation within organelles.

For the last cluster, containing only VPA (**Figure [6](#F6){ref-type="fig"}**) at low, middle and high doses, FA degradation, PPAR signaling pathway and retinol metabolism, all of them involved in the elimination of FAs are up regulated. This compound produces a strong effect on the metabolism of FAs and lipids and therefore the cells react with increasing the pathway activities associated with FA degradation.

So, it is interesting to see that, each of the cluster shows some pathway deregulation related lipid metabolism, FA degradation, glycolysis or PPAR signaling pathway, all related to steatosis.

Discussion
==========

The conventional assumption that a drug acts selectively on a single target is shifting toward "drug-holistic" systems based approaches. Similarly, a disease or a toxicity endpoint reflects not only the impairment of a unique gene. In fact, the disruption of many genes and pathways can lead to a disease or a specific toxicity. In the case of steatosis, we have focused the study on trying to understand the underlying mechanisms for steatosis using a set of diverse compounds. Considering the MIEs and KEs known to lead to the AOP steatosis (based on AOP-Wiki), our study confirms the deregulation of these biomarkers and highlighted new genes that produce steatosis. With the development of a time-series analysis combined with pathway analysis, it is possible to follow the evolution of the pathways over time and how they are connected to the different stages of steatosis.

Interestingly, the integration of a large and diverse set of compounds in the analysis pinpoints their specificity in leading to steatosis. However, our results show that the time seems to have a higher impact in the DEGs and pathways analysis than the concentration. The early dedifferentiation of PHH in 2D cultures might explain this observation. It is also possible that the global normalization reduces the specific signal of some genes. Additionally, for more than half of the compounds studied, only two times points have been tested experimentally, which might influence the results.

In our study, the compounds have been tested in PHH and the translation to human liver tissue would be of great interest to validate these outcomes. Some rats *in vivo* data beyond the 24 h time point are available in TG-GATEs and could be analyzed similarly in order to evaluate the overlap between *in vitro* and *in vivo* data. Finally, it has been reported that 3D cell cultures could be a more suitable system to mimic human organs that 2D cultures ([@B18]) and it would be interesting to assess the steatogenic effect of these compounds in this 3D spheroid system.

To summarize, most of the genes that are associated with a steatosis AOP, described in AOP wiki, have been found in our study. The integration of the previously published information on steatosis with the newly found genes and pathways from our analysis can enrich the knowledge of developed AOPs on steatosis. The **Figure [7A](#F7){ref-type="fig"}** represents an AOP network, i.e., the result of an accumulation of a number of individual AOPs listed on the AOP Wiki website. The list of AOPs used for the completion of the full steatosis pathway is: 34 (LXR activation leading to hepatic steatosis), 36 (Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis), 57 (AhR activation leading to hepatic steatosis), 58 (NR1I3 (CAR) suppression leading to hepatic steatosis), 60 (NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis), 61 (NFE2L2/FXR activation leading to hepatic steatosis). Besides, the capture of coenzyme A by VPA was added to the mechanistic pathway ([@B57]), as well as oxidative stress ([@B60]). In this figure, we can see direct (and indirect) interaction between genes suggested by the analysis and known genes. For example, TSPAN6 deregulates oxidative phosphorylation, which acts on the mitochondrial β-oxidation. The deregulation of ALDH7A1 will lead to a higher production of lipids and impact the oxidative stress with a reduction of β-oxidation. In contrast, PON2 impacts the immune system. We looked also at the cellular compartmental level and how the genes deregulation can perturb the interaction with each other and lead to steatosis (**Figure [7B](#F7){ref-type="fig"}**). We can see that all the cell compartments can be involved in steatosis, many of which undertake functions within the mitochondria and the nucleus. More specifically, perturbation in endoplasmic reticulum and vesicles through the genes MUL1, TMEM135, OSBPL9, SCD1, SREBP-1C, GPAT3 can lead to steatosis.

![**(A)** Adverse Outcome Pathway related to steatosis network, which summarizes a collection of information across several AOPs. The yellow boxes represent known genes and key events associated to steatosis. The blue color shows the newly suggested genes and pathways involved in the AOPs. Only compounds to which there is a higher likelihood to affect the MIE or KE than other compounds have been introduced in the AOP. In **(B)** the different cell compartments and how the interact with each other in the pathways that lead to steatosis.](fgene-09-00396-g007){#F7}

Other studies have reported computational approaches to leverage large-scale toxicogenomic information, biological pathways and high throughput data for the identification of toxicity pathways. For example, [@B10] described a computational approach in which curated biological pathways and high-throughput toxicity data are used to identify toxicity pathways. This computational method uses a data-driven approach to assemble an AOP, which allows for the integration of biological information into pathway-based networks and can be updated with new information. Coupling both approaches could be interesting in the enrichment of the steatosis AOPs.

Overall, our findings illustrate how an integrative computational chemical system biology approach can be used to study steatosis and obtain new metabolic pathways that are deregulated during the process of liver injury by chemical exposure. Obviously, these findings need to be further validated with additional experimental studies. These associations are potentially not causative but more reflect biomarkers along the pathway to develop steatosis. In many case, changes in gene expression are a response to a stressor and it is only when these adaptive changes are overwhelmed that the adverse effect occurs.
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